INVEGA TRINZA® Common Dosing and Administration Topics
Transition to INVEGA TRINZA®
Transition from Other LAI Antipsychotics (Other than INVEGA SUSTENNA® or RISPERDAL CONSTA®)
Consistent with the INVEGA TRINZA® Prescribing Information:
For Schizophrenia: Patients may transition from a monthly Long-Acting Injectable Antipsychotic (at steady-state) to monthly INVEGA SUSTENNA® (with adequate treatment for at least 4 months) to every 3-month INVEGA TRINZA®. See the respective Prescribing Information for complete information.
When transitioning a patient from another LAI Antipsychotic to INVEGA SUSTENNA® to INVEGA TRINZA®, it is important to note:
INVEGA SUSTENNA® Dosing: When transitioning patients currently at steady-state on another long-acting injectable antipsychotic, initiate INVEGA SUSTENNA® therapy in place of the next scheduled injection. The first dose of INVEGA SUSTENNA® should be 234 mg in the deltoid muscle (per the INVEGA TRINZA® Prescribing Information). INVEGA SUSTENNA® should then be continued at monthly intervals. Based on previous clinical history of tolerability and/or efficacy, some patients may benefit from lower or higher maintenance doses within the available strengths. Monthly maintenance doses can be administered in either the deltoid or gluteal muscle. The last two doses of INVEGA SUSTENNA® must be the same dosage strength before starting INVEGA TRINZA®.
INVEGA TRINZA® Dosing: Patients adequately treatment for at least four months with 78 mg, 117 mg, 156 mg, or 234 mg of INVEGA SUSTENNA® were transitioned to 273 mg, 410 mg, 546 mg, or 819 mg, respectively of INVEGA TRINZA® at the next INVEGA SUSTENNA® injection (± 1 week). INVEGA TRINZA® should then be administered every 3 months, slowly deep into the gluteal or deltoid muscle. INVEGA TRINZA® dose adjustments can be made every 3 months in increments within the range of 273 mg to 819 mg based on individual patient tolerability and/or efficacy.